Adverse Drug Reaction Reporting Systems
Pharmacovigilance fundamentals for students and practicing pharmacists.
By Dr. Khalid Mehmood, MD5 min read
Reviewed by Dr. Khalid Mehmood, MD ·
Pharmacovigilance exists because pre-approval trials cannot characterize every rare or delayed harm. Adverse drug reaction (ADR) reporting systems convert individual clinical observations into signals that regulators and manufacturers can investigate. Pharmacists are often the first professionals to hear a credible story — a rash after an antibiotic, a bleed after an anticoagulant change, a seizure after an interaction — and reporting is part of the professional duty, not optional paperwork.
What counts as reportable
Report suspected ADRs, not only proven causality. Include unexpected reactions, serious events (death, hospitalization, disability, congenital anomaly, or other medically important harm), and problems with quality or device use that look like an ADR. Medication errors that caused harm belong in the same safety net. Lack of efficacy can be a signal, especially for biologics, vaccines, and products with known supply or cold-chain risk.
Causality tools such as Naranjo or WHO-UMC categories help you think, but do not wait for a “definite” score. A well-described possible case is more useful than a perfect score with missing dates.
How national and global systems connect
Many countries run a spontaneous reporting program (for example, FDA MedWatch, Yellow Card, or a national pharmacovigilance centre). Reports typically flow to a national database and, for many regulators, into the WHO global database (VigiBase) via the Uppsala Monitoring Centre. Industry has parallel obligations under ICH E2 series: expedited reporting of serious unexpected events and periodic benefit–risk documents.
- Capture drug name, dose, dates, indication, and dechallenge/rechallenge if known.
- List concomitant medicines and relevant labs.
- Describe the event in chronological language, not slogans.
- State seriousness and outcome (recovered, recovering, fatal, unknown).
From a single report to a signal
One case rarely changes a label. Signal detection looks for disproportionate reporting, clusters of a rare event, or a biologically plausible new pattern. After a signal, assessors may request studies, update the SPC/PIL, add a boxed warning, or restrict use. Under-reporting remains the main weakness: busy clinicians skip “known” reactions, and mild events vanish. Reporting the serious and the unexpected is how the system learns.
In the pharmacy, keep the reporting URL or form bookmarked, train every pharmacist on a two-minute minimum dataset, and treat a reported ADR as a clinical intervention: document counseling, alternative therapy, and allergy-record updates so the same harm does not recur at the next fill.
